Ildong Pharmaceutical pursues overseas market development and business diversification
Exploring exports in the fields of cardiovascular complex drugs, anticancer drugs, and antibiotics
Seeking CMO business partnerships based on GMP infrastructure
Attention to GLP-1 obesity medicine, P-CAB gastrointestinal medicine, etc.
Ildong Pharmaceutical announced on the 10th that it participated in ‘CPhI Worldwide’, a pharmaceutical and bio exhibition held in Milan, Italy, and announced its own competitiveness, including active pharmaceutical ingredients (API), new drug candidates, original technology, and manufacturing infrastructure.
‘CPhI Worldwide (Convention on Pharmaceutical Ingredients Worldwide)’ is one of the world’s largest exhibitions in the pharmaceutical and bio fields. This year, it will be held from the 8th to the 10th (local time).
Ildong Pharmaceutical participated in this expo as part of its drive to explore overseas markets and diversify its business. An exhibition booth was set up in the Korean pavilion at the event venue and partnering meetings were held with a number of overseas companies for business development and partnerships. Ildong Pharmaceutical is seeking to expand its overseas business, focusing on the Southeast Asian market. Currently, we are exporting combination drugs for treating cardiovascular diseases (Telostop, Two Tops, Drop Top, etc.) to Southeast Asia. At the expo site, product competitiveness was emphasized by introducing anticancer drugs, antibiotics, and wound care dressings (MediTouch) as global business items.
They also showed great effort in the pharmaceutical contract manufacturing (CMO) business. Ildong Pharmaceutical has excellent pharmaceutical manufacturing and quality management (GMP) infrastructure, including standalone antibiotic and anticancer drug production facilities. In the field of new drug development, emphasis is placed on securing partners to promote commercialization of candidate substances. Currently, we have secured a pipeline of new drugs in various fields, including metabolic diseases, gastrointestinal diseases, and degenerative diseases, and are in the process of commercialization, including clinical development.
At this expo, Ildong Pharmaceutical presented a GLP-1 (glucagon-like peptide-1) receptor agonist mechanism oral synthetic new drug candidate targeting diabetes and obesity (ID110521156) and a P-CAB (potassium competitive gastric acid secretion inhibitor) class peptic ulcer treatment (ID120040002). ), an adenosine A1·A2A receptor dual antagonist (ID119040338) being developed as a treatment for Parkinson’s disease, and a treatment for metabolic abnormality-related steatohepatitis (MASH) (ID119031166).
An official from Ildong Pharmaceutical said, “We will expand our business area to the healthcare field, including health functional foods and cosmetics as well as existing finished products and raw drug products, and pursue a global strategy through development partnerships for new drug pipelines, technology export (licensing out), and CMO business.” “We plan to diversify,” he said.
Kim Min-beom, Donga.com reporter mbkim@donga.com